Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives $20.83 Average Target Price from Analysts

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) have been assigned a consensus recommendation of "Buy" from the nine research firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $20.83.

A number of research firms have weighed in on STOK. Leerink Partners started coverage on Stoke Therapeutics in a report on Monday, October 14th. They set an "outperform" rating and a $18.00 price objective on the stock. HC Wainwright reissued a "buy" rating and set a $35.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, November 6th. Needham & Company LLC reiterated a "buy" rating and set a $22.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, November 6th. Leerink Partnrs upgraded shares of Stoke Therapeutics to a "strong-buy" rating in a research report on Friday, October 11th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Stoke Therapeutics in a research note on Tuesday.

Stoke Therapeutics Stock Down 5.1 %

NASDAQ STOK traded down $0.66 during trading on Thursday, hitting $12.32. The company's stock had a trading volume of 393,508 shares, compared to its average volume of 746,966. Stoke Therapeutics has a 52 week low of $4.09 and a 52 week high of $17.58. The firm has a 50 day moving average price of $12.48 and a 200 day moving average price of $13.67. The firm has a market cap of $652.59 million, a P/E ratio of -5.87 and a beta of 0.95.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.05. The company had revenue of $4.89 million for the quarter, compared to analyst estimates of $3.46 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. On average, equities analysts expect that Stoke Therapeutics will post -2.03 earnings per share for the current year.

Insider Activity

In other Stoke Therapeutics news, insider Barry Ticho sold 10,000 shares of the firm's stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $12.07, for a total transaction of $120,700.00. Following the transaction, the insider now owns 51,277 shares in the company, valued at approximately $618,913.39. This trade represents a 16.32 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Edward M. Md Kaye sold 6,170 shares of the company's stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $12.78, for a total value of $78,852.60. Following the completion of the sale, the chief executive officer now directly owns 68,671 shares of the company's stock, valued at approximately $877,615.38. This trade represents a 8.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 2,000,349 shares of company stock valued at $28,031,296. 11.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Stoke Therapeutics

Several large investors have recently modified their holdings of STOK. Lynx1 Capital Management LP grew its position in shares of Stoke Therapeutics by 40.3% in the 2nd quarter. Lynx1 Capital Management LP now owns 5,185,191 shares of the company's stock valued at $70,052,000 after purchasing an additional 1,488,371 shares during the period. RTW Investments LP increased its position in shares of Stoke Therapeutics by 10.1% during the third quarter. RTW Investments LP now owns 4,652,285 shares of the company's stock worth $57,177,000 after acquiring an additional 427,447 shares in the last quarter. State Street Corp raised its holdings in shares of Stoke Therapeutics by 8.6% during the third quarter. State Street Corp now owns 1,728,888 shares of the company's stock worth $21,248,000 after acquiring an additional 137,145 shares during the period. Assenagon Asset Management S.A. bought a new stake in Stoke Therapeutics in the 2nd quarter valued at $19,835,000. Finally, Healthcare of Ontario Pension Plan Trust Fund boosted its stake in Stoke Therapeutics by 426.1% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company's stock worth $18,741,000 after purchasing an additional 1,123,500 shares during the period.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.